AbbVie acquired Capstan, including its lead asset CPTX2309, a potential first-in-class in vivo targeted lipid nanoparticle (tLNP) anti-CD19 CAR-T therapy candidate for the treatment of B cell-mediated autoimmune diseases. Additionally, AbbVie has acquired Capstan’s proprietary tLNP platform technology designed to deliver RNA payloads, such as mRNA, capable of engineering specific cell types in vivo. Capstan was co-founded in 2021 and newsletter subscribers can learn more about the company including the Penn Medicine and Pen Vet affiliated scientific co-founders here. Read more about the acquisition by AbbVie here.